The International Myeloma Foundation is very pleased that Sarclisa (isatuximab-irfc), a monoclonal antibody that binds to the CD38 receptor on multiple myeloma cells, has just been approved by the FDA.

This approval means patients with relapsed/refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor have a new option.

Approval was based upon the ICARIA-MM study in which patients received a combination of Sarclisa plus pomalidomide and dexamethasone (pom/dex) versus pom/dex alone. The risk of progression was reduced by 40%, a very meaningful improvement in outcome. It is excellent to have one more potent agent available for relapsing patients.

--comments by Dr. Brian G.M. Durie, IMF Chairman of the Board

Read the full press release on the Sarclisa approval here.



Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.